Finance

Lists
Why is EDIT up 2.11%?
Dive Deeper
EDIT:NASDAQ
Editas Medicine Inc
$2.90
+2.11%
(+0.060) 1D
$2.91
+0.34% (+0.0100)
Pre-market
Closed: Oct 9, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for EDIT...
Open
$2.85
High
$2.97
Low
$2.71
Mkt. cap
445.38M
Avg. vol.
2.98M
Volume
390.00
52-wk high
$4.33
52-wk low
$1.66
EPS
-$0.74
Beta
2.00
Shares outstanding
153.58M
No. of employees
87
Open
$2.85
High
$2.97
Low
$2.71
Mkt. cap
445.38M
Avg. vol.
2.98M
Volume
390.00
52-wk high
$4.33
52-wk low
$1.66
EPS
-$0.74
Beta
2.00
Shares outstanding
153.58M
No. of employees
87
News stories
From web sources and news partners
Profile
Editas Medicine, Inc., is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado. Wikipedia
About Editas Medicine Inc
CEO-
Employees87
FoundedNov 2013
Headquarters-
SectorBiotechnology
Websiteeditasmedicine.com
Analyst ratings
Based on 8 analysts giving stock ratings to EDIT in the past 3 months
Buy
Buy
6
Hold
1
Sell
1
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for EDIT in the last 3 months.
Highest
Current $2.90
$8.00 (+175.86%)
Average
$5.67 (+95.52%)
Lowest
$4.00 (+37.93%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yanan Zhu
Wells Fargo
Buy
Upgraded
$6.00
+106.9%
10/08/2026
Debjit Chattopadhyay
Guggenheim
Buy
Upgraded
$5.00
+72.4%
09/23/2026
Rick Bienkowski
Ladenburg Thalmann & Co.
Buy
Initiated
$6.00
+106.9%
08/18/2026
Alec Stranahan
Bank of America Securities
Sell
Reiterated
-
-
08/07/2026
Luca Issi
RBC Capital
Hold
Maintained
$4.00
+37.9%
08/05/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$5.00
+72.4%
08/06/2026
Phil Nadeau
TD Cowen
Buy
Maintained
-
-
08/05/2026
Boris Peaker
JonesTrading
Buy
Maintained
$8.00
+175.9%
08/05/2026
Jonathan Miller
Evercore ISI
Buy
Maintained
$15.00
+417.2%
05/27/2026
Geulah Livshits
Chardan Capital
Buy
Reiterated
$4.00
+37.9%
05/05/2026
Soumit Roy
JonesTrading
Buy
Maintained
$8.00
+175.9%
04/06/2026
Joon Lee
Truist Financial
Hold
Maintained
-
-
03/17/2026
Brian Cheng
J.P. Morgan
Sell
Maintained
-
-
03/13/2026
William Maughan
Clear Street
Buy
Maintained
$4.60
+58.6%
03/10/2026
Last report
Aug 5, 2026
Fiscal period
Q2 2026
-$0.15 / -$0.28
+46.23%beat
Revenue / Est. (USD)
11.89M / 2.89M
+311.54%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
7.54M
24.74M
2.83M
11.89M
Cost of goods sold
19.78M
27.40M
17.60M
20.18M
Cost of revenue
19.78M
27.40M
17.60M
20.18M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
12.32M
11.35M
10.23M
11.60M
Operating expense
12.32M
11.35M
10.23M
11.60M
Total operating expenses
32.09M
38.76M
27.83M
31.78M
Operating income
-24.55M
-14.02M
-25.00M
-19.89M
Other non operating income
-1.00K
2.18M
-113.00K
17.00K
EBT including unusual items
-25.12M
-5.62M
-24.98M
-18.23M
EBT excluding unusual items
-25.12M
-9.69M
-24.98M
-19.57M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-25.12M
-5.62M
-24.98M
-18.23M
Net profit margin
-332.98%
-22.72%
-882.44%
-153.32%
Earnings per share
-0.28
-0.06
-0.26
-0.15
Interest and investment income
1.83M
2.14M
1.21M
1.37M
Interest expense
-2.40M
-
-1.07M
-1.06M
Net interest expenses
-568.00K
2.14M
134.00K
307.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-23.83M
-13.21M
-24.52M
-19.48M
Gain or loss from assets sale
-
34.00K
-
111.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps